Noteworthy Rating Filing: AstraZeneca PLC (LON:AZN) Investors: HSBC Reaffirms “Hold” Rating, Sees GBX 4700.00/Share

November 23, 2016 - By Adrian Mccoy

AstraZeneca PLC (LON:AZN) Rating

In a research note revealed to clients on today, HSBC kept their “Hold” rating on AstraZeneca PLC (LON:AZN)‘s stock. The PT means a potential upside of 11.80% from company’s previous stock close.

AstraZeneca plc (LON:AZN) Ratings Coverage

Out of 30 analysts covering AstraZeneca PLC (LON:AZN), 13 rate it a “Buy”, 4 “Sell”, while 13 “Hold”. This means 43% are positive. GBX 7000 is the highest target while GBX 3700 is the lowest. The GBX 4922.09 average target is 17.19% above today’s (GBX 4200) stock price. AstraZeneca PLC has been the topic of 340 analyst reports since July 23, 2015 according to StockzIntelligence Inc. Societe Generale maintained AstraZeneca plc (LON:AZN) rating on Thursday, September 10. Societe Generale has “Buy” rating and GBX 6600 price target. On Friday, December 18 the stock rating was maintained by Bernstein with “Market Perform”. As per Monday, October 26, the company rating was maintained by UBS. The firm earned “Buy” rating on Monday, November 30 by Deutsche Bank. Citigroup maintained AstraZeneca plc (LON:AZN) rating on Friday, May 6. Citigroup has “Buy” rating and GBX 5400 price target. The rating was maintained by Cantor Fitzgerald on Thursday, July 28 with “Buy”. The firm earned “Buy” rating on Thursday, November 10 by Cantor Fitzgerald. The stock has “Hold” rating given by Helvea on Thursday, December 17. The stock of AstraZeneca plc (LON:AZN) earned “Neutral” rating by JP Morgan on Monday, October 3. Jefferies maintained AstraZeneca plc (LON:AZN) on Monday, October 12 with “Buy” rating.

About 718,402 shares traded hands. AstraZeneca plc (LON:AZN) has risen 2.98% since April 25, 2016 and is uptrending. It has underperformed by 2.35% the S&P500.

AstraZeneca PLC is a biopharmaceutical company. The company has a market cap of 53.42 billion GBP. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. It has a 26.78 P/E ratio. The Firm has its activities in over 100 countries.

According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.”

AZN Company Profile

AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a biopharmaceutical company. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Firm has its activities in over 100 countries. The Company’s pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development.

Another recent and important AstraZeneca plc (LON:AZN) news was published by Streetinsider.com which published an article titled: “Form 6-K ASTRAZENECA PLC For: Nov 22” on November 22, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>